Cover Image

Anti PD-1/Anti PDL-1 Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Meta-Analysis of Phase 2/3 Randomized Controlled Trials

<b>Importance:</b> Immune checkpoint inhibitors (ICI) have revolutionized the treatment for gastroesophageal cancers (GEC). It is important to investigate the factors that influence the response to anti-PD-1/PD-L1 ICIs. <b>Objective:</b> To assess the benefits of PD-1/PD-L1 I...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kanak Parmar (Author), Sai Subramanyam (Author), Kristopher Attwood (Author), Duke Appiah (Author), Christos Fountzilas (Author), Sarbajit Mukherjee (Author)
Format:	Book
Published:	MDPI AG, 2022-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Machine-Learning Guided Discovery of Bioactive Inhibitors of PD1-PDL1 Interaction
by: Sachin P. Patil, et al.
Published: (2022)

Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis
by: Yi Huang, et al.
Published: (2024)

Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
by: Yiting Sun, et al.
Published: (2021)

Psoriasis y anti-PD1/anti-PDL1: presentación de tres casos, revisión de la literatura y propuesta de algoritmo de manejo
by: E. Sánchez-Martínez, et al.
Published: (2022)

Is a triggering role or a causative role of PD-1/PDL-1 inhibitors in the development of paraneoplastic dermatomyositis?
by: Michela Starace, et al.
Published: (2022)

Immunotherapy using PD‑1/PDL-1 inhibitors in triple‑negative breast cancer: a systematic review
by: Dione Tavares, et al.
Published: (2021)

Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer
by: Liting Sun, et al.
Published: (2023)

New view on alcoholic liver disease - potential role of PD1/PDL-1 pathway in the disease pathogenesis
by: Katarzyna Adamczyk, et al.
Published: (2019)

Idiopathic CD4 T Cell Lymphocytopenia: A Case of Overexpression of PD-1/PDL-1 and CTLA-4
by: Gaurav Kumar, et al.
Published: (2021)

Impaired in vitro Interferon-γ production in patients with visceral leishmaniasis is improved by inhibition of PD1/PDL-1 ligation.
by: Yegnasew Takele, et al.
Published: (2022)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
by: Giuseppe Luigi Banna, et al.
Published: (2020)

Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro
by: Amy H. Lin, et al.
Published: (2017)

Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials
by: Lihu Gu, et al.
Published: (2022)

Hepatoid adenocarcinoma of lung: A diagnostic challenge - Series of six cases with histopathological, predictive molecular and PD.L1 assessment
by: Sunil Pasricha, et al.
Published: (2021)

Anti-PD-1-Induced Hidradenitis Suppurativa
by: Alexia Maillard, et al.
Published: (2021)

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
by: Sonam Puri, et al.
Published: (2020)

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
by: Ze Xiang, et al.
Published: (2022)

Stimulation of MMP-1 and CCL2 by NAMPT in PDL Cells
by: Marjan Nokhbehsaim, et al.
Published: (2013)

The selection of immune checkpoint inhibitors of programmed cell death (anti-PD-1) and its ligand (anti-PD-L1) makes matters more challenges for clinical practice
by: Peng-Hui Wang, et al.
Published: (2024)

Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)
by: John Powderly, et al.
Published: (2021)

Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
by: Long Ma, et al.
Published: (2021)

GDF15 Contributes to the Regulation of the Mechanosensitive Responses of PdL Fibroblasts through the Modulation of IL-37
by: Julia Steinmetz, et al.
Published: (2024)

Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA
by: Wenxin Zhang, et al.
Published: (2023)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
by: Yihang Qi, et al.
Published: (2021)

Evaluation of the Expression of Immunohistochemical Staining of PDL1 in Renal Cell Cancer
by: Rihab Mohammed Edress Al-Nuaimy, et al.
Published: (2024)

Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
by: Yating Zhao, et al.
Published: (2021)

[Translated article] Psoriasis and Anti-PD-1 and Anti-PD-L1 Immunotherapy: Three Cases, a Review of the Literature, and a Proposed Management Algorithm
by: E. Sánchez-Martínez, et al.
Published: (2022)

An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
by: Sarah C. Cowles, et al.
Published: (2022)

Product review: avelumab, an anti-PD-L1 antibody
by: Julie M. Collins, et al.
Published: (2019)

Product review on the Anti-PD-L1 antibody atezolizumab
by: Neil J. Shah, et al.
Published: (2018)

Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress
by: Ziwei Li, et al.
Published: (2024)

Preclinical Characterization of a Novel Anti-Cancer PD-L1 Inhibitor RPH-120
by: Andrey Kulikov, et al.
Published: (2021)

The Presence of PDL-1 on CD8+ Lymphocytes Is Linked to Survival in Neonatal Sepsis
by: Lyudmila L. Akhmaltdinova, et al.
Published: (2022)

A comparative study to assess the increased expression of programmed cell death-1 (PD1) and programmed cell death- ligand-1 (PDL1) in oral potentially malignant disorders and oral squamous cell carcinoma
by: Sonalika Srivastava, et al.
Published: (2023)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
by: He YY, et al.
Published: (2018)

Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy
by: Baijia Jiang, MD, et al.
Published: (2018)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
by: Peng-Fei Wang, et al.
Published: (2017)

Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov
by: Zelei Dai, et al.
Published: (2023)

Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in vivo: AMC-095 Study
by: SharonR Lewin, et al.
Published: (2019)

Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework
by: Jessica C. Leete, et al.
Published: (2022)